<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03593421</url>
  </required_header>
  <id_info>
    <org_study_id>20171060</org_study_id>
    <secondary_id>sPIF-US-PRA-001</secondary_id>
    <nct_id>NCT03593421</nct_id>
  </id_info>
  <brief_title>Phase 2 Dose Finding sPIF in Patients With High Panel Reactive Antibodies</brief_title>
  <official_title>Phase II, Open Label Adaptive Design Dose Finding Study to Investigate Effect of Synthetic PreImplantation Factor (sPIF) in Patients With High Panel Reactive Antibodies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Christopher O'Brien, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioIncept LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open labeled dose finding adaptive design study. Patients with elevated cPRA
      values, 30-60% will be recruited and administered sPIF injected subcutaneously for 14 doses;
      one dose on Monday, Wednesday, Friday, or Tuesday, Thursday, Saturday, per individual patient
      dialysis schedule.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine the sPIF dose that reduces serum cPRA to &lt;30%, when
      administered 14 doses. Safety, tolerability, and efficacy will be evaluated at day 42 and and
      day 84. The suitability of a patient to receive a kidney transplant will also be monitored up
      to 6 months after Day 84. Safety and tolerability will be assessed at each of the increased
      doses and throughout the treatment duration. Exploratory analysis of blood indices will be
      carried out and changes based on history, physical and laboratory exams will be assessed
      according to the 12 systems.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    BioInceptdecided not to pursue this drug target at this time.
  </why_stopped>
  <start_date type="Anticipated">February 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>open label, adaptive design, dose finding study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the safety and tolerability of multiple ascending, subcutaneously administered doses of sPIF in patients with high panel reactive antibodies (PRA) with no SAEs greater than grade 3</measure>
    <time_frame>84 days</time_frame>
    <description>No grade SAE &gt; Grade 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the pharmacokinetics of sPIF levels in the circulation after multiple ascending, subcutaneously administered doses of sPIF by measurement of sPIF in circulation</measure>
    <time_frame>84 days</time_frame>
    <description>sPIF circulating levels are assessed following dialysis and post-first injection at 1, 2, and 4 hours and before last sPIF dose, trough values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the effect of sPIF on serum cPRA following administration of multiple ascending, subcutaneously administered doses as determined by CPRA levels</measure>
    <time_frame>84 days</time_frame>
    <description>Determine cPRA levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the percentage of patients in remission ass determined by CPRA less than 30%</measure>
    <time_frame>84 days</time_frame>
    <description>Determine cPRA levels as defined by &lt;30% until day 42, and sustained until day 84. Analysis is based on decrease in cPRA percent, median fluorescent intensity (MFI) and standard fluorescent intensity (SFI) analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess number of patients receiving a kidney transplant within 6 months post-day 84 as dertermined by patients being available for kidney transplant</measure>
    <time_frame>6 months post study drug treatment</time_frame>
    <description>Determine number of patients eligible for kidney transplant</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Panel Reactive Antibodies</condition>
  <arm_group>
    <arm_group_label>synthetic preImplantation factor 1 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be dosed SQ with 14 doses of sPIF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>synthetic preImplantation factor 2 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be dosed SQ with 14 doses of sPIF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>synthetic preImplantation factor 3 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be dosed SQ 14 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>synthetic preImplantation factor 4 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be dosed SQ with 14 doses of sPIF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>synthetic preImplantation factor 5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be dosed SQ with 14 doses of sPIF</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>synthetic PreImplantation Factor</intervention_name>
    <description>peptide</description>
    <arm_group_label>synthetic preImplantation factor 1 mg/kg</arm_group_label>
    <arm_group_label>synthetic preImplantation factor 2 mg/kg</arm_group_label>
    <arm_group_label>synthetic preImplantation factor 3 mg/kg</arm_group_label>
    <arm_group_label>synthetic preImplantation factor 4 mg/kg</arm_group_label>
    <arm_group_label>synthetic preImplantation factor 5 mg/kg</arm_group_label>
    <other_name>sPIF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatient male and females 18-75 years old

          -  Able and willing to give written informed consent and comply with the requirements of
             the study protocol

          -  Calculated panel reactive antibody (cPRA) &gt;30% and &lt;60% with a threshold using mean
             fluorescent intensity (MFI) of 3,000 or standard fluorescence intensity (SFI) of
             60,000 over six months.

          -  Women who are of childbearing potential must have a negative serum pregnancy test
             prior to being enrolled in the study and agree to use effective method of
             contraception throughout the 84-day study.

          -  Patients on kidney dialysis 3.3 Exclusion Criteria

          -  Patients not capable of following through the treatment for various reasons as
             determined by treating physicians

          -  Pregnant females

          -  Requiring blood transfusions

          -  Have an active infection

          -  Infection with hepatitis C virus (HCV) or hepatitis B virus(HBV) or human
             immunodeficiency virus (HIV), lack of documentation of treatment of a positive PPD,
             baseline leukopenia, white blood cell count (WBC) &lt;4.0, thrombocytopenia (platelet
             count &lt;100,000/mm) or difficult to treat anemia, a hematocrit chronically &lt;25% on
             intravenous iron and EPO (erythropoietin) therapy

          -  Active cancer within 5 years

          -  Significant cardiac or pulmonary disease (including obstructive pulmonary disease)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>eytan barnea, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>BioIncept LLC</affiliation>
  </overall_official>
  <reference>
    <citation>Barnea ER, Rambaldi M, Paidas MJ, Mecacci F. Reproduction and autoimmune disease: important translational implications from embryo-maternal interaction. Immunotherapy. 2013 Jul;5(7):769-80. doi: 10.2217/imt.13.59. Review.</citation>
    <PMID>23829627</PMID>
  </reference>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>June 7, 2018</study_first_submitted>
  <study_first_submitted_qc>July 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2018</study_first_posted>
  <last_update_submitted>December 31, 2018</last_update_submitted>
  <last_update_submitted_qc>December 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Christopher O'Brien, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

